COMMUNIQUÉS West-GlobeNewswire

-
Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts
09/07/2019 -
TRHC and CQuentia Announce Collaboration to Leverage Scientific and Technology Resources to Provide Pharmacogenomic Services and Biometric Wearable Products to Patients and Providers
09/07/2019 -
Skin health startup Derm-Biome Pharmaceuticals, Inc. to receive funding from the Government of Canada
09/07/2019 -
BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA®
09/07/2019 -
Medical Research Council Funds Phase 2 Multi-Center Study of XBiotech’s Bermekimab in Advanced Cancer Patients
09/07/2019 -
Lutronic Vision to Present R:GEN™ Efficacy Data at 19th EURETINA Congress
09/07/2019 -
NICE Issues Draft Guidance on the Use of gammaCore for Cluster Headache
09/07/2019 -
CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration
09/07/2019 -
GBT Announces New Employment Inducement Grants
09/07/2019 -
Immutep Raises A$10 Million Via Private Placement and Underwritten Entitlement Offer
09/07/2019 -
Inovalon Reaches Milestone and Achieves Integration With Epic
09/07/2019 -
ProMIS Neurosciences’ Data for Alzheimer’s Disease Clinical Candidate PMN310 Published in Scientific Reports
09/07/2019 -
Helix BioPharma Corp. Submits L-DOS47 IND Application With U.S. FDA for Pancreatic Cancer
09/07/2019 -
Metacrine Doses First Patient in 12-Week NASH Proof-of-Concept Trial with a Sustained FXR Agonist
09/07/2019 -
CB2 Insights and Premier Health Group Move to Second Phase of Primary Care Physician Tools for Medical Cannabis Evaluations
09/07/2019 -
YSS Corp. Announces Receipt of Five Additional Cannabis Retail Licenses in Alberta, Doubling Currently Licensed Stores to Ten
09/07/2019 -
Engage Therapeutics Announces Data from Phase 2a, Proof-of-concept Study of Staccato Alprazolam to Suppress Seizures in Patients with Epilepsy Published in Epilepsia
09/07/2019 -
Cronos Group Appoints Dr. Todd Abraham as Chief Innovation Officer
09/07/2019 -
Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to Optimize Ocular Oncology Drug Delivery
09/07/2019
Pages